



Eriodictyol Inhibits the Production and Gene Expression of MUC5AC Mucin via the I κ B α -NF- κ B p65 Signaling Pathway in Airway Epithelial Cells

Chawon Yun¹, Hyun Jae Lee^{2,*} and Choong Jae Lee^{1,*}

¹Department of Pharmacology, School of Medicine, Chungnam National University, Daejeon 35015,

²Smith Liberal Arts College and Department of Addiction Science, Graduate School, Sahmyook University, Seoul 01795, Republic of Korea

Abstract

In this study, we investigated whether eriodictyol exerts an effect on the production and gene expression of MUC5AC mucin in human pulmonary epithelial NCI-H292 cells. The cells were pretreated with eriodictyol for 30 min and then stimulated with phorbol 12-myristate 13-acetate (PMA) for 24 h. The effect of eriodictyol on PMA-induced nuclear factor kappa B (NF- κ B) signaling pathway was also investigated. Eriodictyol suppressed the MUC5AC mucin production and gene expression induced by PMA via suppression of inhibitory kappa B α degradation and NF- κ B p65 nuclear translocation. These results suggest that eriodictyol inhibits mucin gene expression and production in human airway epithelial cells via regulation of the NF- κ B signaling pathway.

Key Words: MUC5AC, Pulmonary mucin, Eriodictyol

INTRODUCTION

Airway mucus is a thin gel-like layer lining the airway luminal surface that consists of water, ions, and various molecules that show antimicrobial and anti-oxidative activities (Adler and Li, 2001). Mucus glycoproteins (mucins) that confer mucus viscoelasticity form a major biological macromolecular component of mucus. In normal lung physiology, airway mucus exerts its function as a physical defensive barrier against airway epithelial damage induced by inhaled dust, irritating gases, and microbes, such as bacteria and viruses, thereby protecting the pulmonary system (Lillehoj and Kim, 2002). However, under the pathological state of the pulmonary system, such as chronic obstructive pulmonary diseases, cystic fibrosis, and asthma, the hyperproduction and/or hypersecretion of airway mucus, indicating the changes in mucin quality or quantity, have been reported to compromise the host defense system, ultimately leading to increased morbidity and mortality (Rose and Voynow, 2006). Although mucolytics, expectorants, and glucocorticoids have been clinically used for the management of abnormal airway mucus secretion, several drawbacks are associated with their use, including rebound mucus hypersecretion due to airway luminal wall irritation and various adverse

side effects (Li *et al.*, 2020). Thus, it is necessary to develop novel agents that regulate the production and/or secretion of mucins by controlling their biosynthesis and/or degradation.

Achieving this may require investigating natural compounds (derived from diverse medicinal plants that are used empirically for alleviating inflammatory pulmonary diseases), with respect to the activity to regulate abnormal secretion and/or production of mucins. We have reported various natural products that modulate the gene expression, production, and secretion of airway mucins (Kim *et al.*, 2012; Seo *et al.*, 2014; Choi *et al.*, 2019; Li *et al.*, 2020).

According to a multitude of reports, eriodictyol, a flavanone, is present in numerous vegetables, fruits, and medicinal plants; moreover, it shows a broad range of biological activities, including antioxidative, antineoplastic, anti-inflammatory, antidiabetic, neuroprotective, antiobesity, cardioprotective, and hepatoprotective activities (Islam *et al.*, 2020). Eriodictyol exerted anticancer effects on human lung cancer cells (Zhang *et al.*, 2019). Eniafe *et al.* (2018) suggested that eriodictyol may be used for the long-term regulation of asthmatic contraction of bronchial smooth muscle. In addition, Deshpande *et al.* (2020) suggested that eriodictyol can be used as a potential regulator for coronavirus disease 2019 via *in silico* analysis

Open Access <https://doi.org/10.4062/biomolther.2021.091>

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received May 13, 2021 Revised Aug 11, 2021 Accepted Aug 28, 2021

Published Online Sep 27, 2021

*Corresponding Authors

E-mail: hjy1213@syu.ac.kr (Lee HJ), LCJ123@cnu.ac.kr (Lee CJ)

Tel: +82-2-3399-1910 (Lee HJ), +82-42-580-8255 (Lee CJ)

Fax: +82-2-3399-1909 (Lee HJ), +82-42-585-6627 (Lee CJ)

using molecular docking technology.

However, there are no studies about the potential effect of eriodictyol on mucin production and mucin gene expression in airway epithelial cells. Among the many subtypes of human mucins, mucin 5AC (MUC5AC) is known as a major type of airway mucin (Lillehoj and Kim, 2002). In this study, we investigated the effect of eriodictyol on MUC5AC mucin production and gene expression induced by phorbol ester in NCI-H292 cells. The human pulmonary mucoepithelial cell line NCI-H292 is often used for identifying the signaling pathways involved in airway mucin production and gene expression (Li *et al.*, 1997; Takeyama *et al.*, 1999; Shao *et al.*, 2003). In addition, phorbol ester induces airway MUC5AC gene expression and mucin production, and nuclear factor kappa B (NF- κ B) signaling is involved in this activity of phorbol ester in airway epithelial cells (Ishinaga *et al.*, 2005; Laos *et al.*, 2006; Wu *et al.*, 2007; Kim *et al.*, 2012; Choi *et al.*, 2019). Thus, to elucidate the mechanism of eriodictyol, we examined whether it exerts any effect on phorbol ester-induced activation of the NF- κ B signaling pathway in NCI-H292 cells.

MATERIALS AND METHODS

Materials

All chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise stated. Eriodictyol (AV-H19076; purity: 98.0%) was purchased from Avention (Incheon, Korea). Anti-NF- κ B p65 (sc-8008), anti- β -actin (sc-8432), and anti-inhibitory kappa B α (I κ B α ; sc-371) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-inhibitory kappa B kinase (IKK) α/β (Ser176/180; #2687) and phospho-specific anti-I κ B α (serine 32/36; #9246) antibodies were purchased from Cell Signaling Technology Inc (Danvers, MA, USA). Anti-nuclear matrix protein p84 (ab-487) antibody was purchased from Abcam (Cambridge, MA, USA). Goat anti-mouse IgG (#401215) and goat anti-rabbit IgG (#401315) were purchased from Calbiochem (Carlsbad, CA, USA) and used as the secondary antibody.

NCI-H292 cell culture

NCI-H292 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin mixture (100 units/mL and 100 μ g/mL, respectively), and hydroxyethyl piperazineethanesulfonic acid (25 mM) at 37°C in a water-jacketed humidified incubator (5% CO₂, 95% air). For serum deprivation, confluent cells were washed twice with phosphate-buffered saline (PBS) and then cultured in RPMI 1640 with 0.2% FBS for 24 h.

Eriodictyol treatment of cells

After serum deprivation, the cells were pretreated with varying concentrations of eriodictyol for 30 min and treated with phorbol 12-myristate 13-acetate (PMA) at 10 ng/mL for 24 h in serum-free RPMI 1640. Eriodictyol was dissolved in dimethyl sulfoxide and treated in culture medium (final concentration of dimethyl sulfoxide was 0.5%). The final pH values of these solutions were between 7.0 and 7.4. The culture medium and 0.5% dimethyl sulfoxide did not affect mucin gene expression,

production, and expression and activity of molecules involved in NF- κ B signaling pathway in NCI-H292 cells. After 24 h, the cells were lysed with buffer solution containing 20 mM Tris, 0.5% NP-40, 250 mM NaCl, 3 mM ethylenediaminetetraacetic acid (EDTA), 3 mM ethylene glycol tetraacetic acid (EGTA), and protease inhibitor cocktail (Roche Diagnostics, IN, USA) and were collected to measure the production of MUC5AC glycoproteins in a 24-well culture plate. Total RNA was extracted to determine MUC5AC gene expression in a six-well culture plate via reverse transcription polymerase chain reaction (RT-PCR). For western blot analysis, the cells were treated with eriodictyol for 24 h and PMA for 30 min.

Quantitative analysis of MUC5AC mucin

Airway MUC5AC mucin production was measured using enzyme-linked immunosorbent assay. Cell lysates were prepared with PBS at a 1:10 dilution, and 100 μ L of each sample was incubated at 42°C in a 96-well plate until dried. The plates were washed three times with PBS, blocked with 2% bovine serum albumin (fraction V) for 1 h at room temperature, and then washed three times with PBS. The plates were then incubated with 100 μ L 45M1, a mouse monoclonal MUC5AC antibody (NeoMarkers, CA, USA), which was diluted at 1:200 with PBS containing 0.05% Tween 20. After 1 h, the wells were washed three times with PBS, and 100 μ L of horseradish peroxidase-goat anti-mouse IgG conjugate (1:3,000) was dispensed into each well and left to incubate for 1 h, after which the plates were washed three times with PBS. Color reaction was developed with 3,3',5,5'-tetramethylbenzidine peroxide solution and stopped with 1 N H₂SO₄. The absorbance was measured at 450 nm.

Isolation of total RNA and RT-PCR

Total RNA was isolated using the easy-BLUE Extraction Kit (iNtRON Biotechnology, Inc., Gyeonggi, Korea) and reverse transcribed using AccuPower RT Premix (BIONEER Corporation, Daejeon, Korea) according to the manufacturer's instructions. Two micrograms of total RNA were primed with 1 μ g of oligo (dT) in a final volume of 50 μ L (RT reaction). Two microliters of the RT reaction product were PCR-amplified in a 25 μ L using Thermoprime Plus DNA Polymerase (ABgene, Rochester, NY, USA). *Rig/S15* rRNA, which encodes a small ribosomal subunit protein, a housekeeping gene that was constitutively expressed, was used as a quantitative control. The following primers were used: *MUC5AC*, forward (5'-TGA TCA TCC AGC AGG GCT-3') and reverse (5'-CCG AGC TCA GAG GAC ATA TGG G-3'); *Rig/S15*, forward (5'-TTC CGC AAG TTC ACC TAC C-3') and reverse (5'-CGG GCC GGC CAT GCT TTA CG-3'). The PCR mixture was denatured at 94°C for 2 min followed by 40 cycles at 94°C for 30 s, 60°C for 30 s, and 72°C for 45 s. After PCR, 5 μ L of the PCR product was subjected to 1% agarose gel electrophoresis and then visualized with ethidium bromide under a transilluminator.

Whole cell extract preparation

NCI-H292 cells (confluent in 100-mm culture dish) were pretreated for 24 h at 37°C with 1, 5, 10, or 20 μ M of eriodictyol and then stimulated with PMA (50 ng/mL) in serum-free RPMI 1640 for 30 min. After eriodictyol treatment, media were aspirated and the cells were washed with cold PBS. For the cell collection, the cells were scraped and centrifuged at 3,000 rpm for 5 min. After the supernatant was discarded, the cell




Fig. 1. Effect of eriodictyol on PMA-induced *MUC5AC* gene expression in NCI-H292 cells. NCI-H292 cells were pretreated with varying concentrations of eriodictyol for 30 min and stimulated with PMA (10 ng/mL) for 24 h. Cell lysates were collected for measurement of *MUC5AC* gene expression using RT-PCR. Three independent experiments were performed, and the representative data are shown. *Significantly different from control ($p < 0.05$). †Significantly different from PMA alone ($p < 0.05$). cont, control; E, eriodictyol. Concentration unit is μM .

pellet was mixed with radioimmunoprecipitation assay buffer [25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)] for 30 min with continuous agitation. The lysate was centrifuged in a microcentrifuge at 14,000 rpm for 15 min at 4°C. The supernatant was either used or immediately stored at -80°C. The amount of protein in extract was quantified using the Bradford method.

Nuclear and cytosolic extract preparation

After treatment with eriodictyol, the cells were harvested using trypsin-EDTA solution and then centrifuged in a microcentrifuge at 1,200 rpm for 3 min at 4°C. After the supernatant was discarded, the cell pellet was washed by suspending in PBS. The cytoplasmic and nuclear protein fractions were extracted using NE-PER® nuclear and cytoplasmic extraction reagent (Thermo-Pierce Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Both extracts were stored at -20°C. The amount of protein in the extracts was quantified using the Bradford method.

Western blot analysis

Whole cell, cytosolic, and nuclear extracts containing proteins (each 50 μg) were subjected to 10% SDS polyacrylamide gel electrophoresis and then transferred onto a polyvinylidene difluoride membrane. The blots were blocked with 5% skimmed milk and probed with the appropriate primary antibody in blocking buffer overnight at 4°C. The membrane was washed with PBS and then probed using the horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were detected using an enhanced chemiluminescence kit (Pierce ECL western blotting substrate; Thermo-Pierce Scientific).

Statistical analysis

The means of individual groups were converted to percent control and expressed as the mean \pm standard error of the mean. The difference between groups was assessed using




Fig. 2. Effect of eriodictyol on PMA-induced *MUC5AC* mucin production in NCI-H292 cells. NCI-H292 cells were pretreated with varying concentrations of eriodictyol for 30 min and stimulated with PMA (10 ng/mL) for 24 h. Cell lysates were collected for measurement of *MUC5AC* mucin production via ELISA. Each bar represents the mean \pm standard error of the mean of three culture wells compared to the control set at 100%. Three independent experiments were performed, and the representative data are shown. *Significantly different from control ($p < 0.05$). †Significantly different from PMA alone ($p < 0.05$). cont, control; E, eriodictyol. Concentration unit is μM .

one-way analysis of variance and the Holm-Sidak test as a post-hoc test. A p -value < 0.05 was considered significantly significant.

RESULTS

Effect of eriodictyol on PMA-induced *MUC5AC* gene expression and mucin production

Eriodictyol suppressed PMA-induced *MUC5AC* gene expression (Fig. 1) and mucin production (Fig. 2), with the latter being dose dependent. As shown in Fig. 2, the amounts of *MUC5AC* mucin in the cells of eriodictyol-treated cultures were as follows: control, 100 \pm 2%; 10 ng/mL of PMA alone, 185 \pm 3%; PMA plus 1 μM eriodictyol, 182 \pm 3%; PMA plus 5 μM eriodictyol, 145 \pm 2%; PMA plus 10 μM eriodictyol, 102 \pm 4%; PMA plus 20 μM eriodictyol, 70 \pm 1%. Cell viability was assessed using the sulforhodamine B assay, which revealed that there was no cytotoxic effect of eriodictyol at concentrations of 1, 5, 10, or 20 μM (data not shown).

Effect of eriodictyol on PMA-induced IKK α/β and I κ B α phosphorylation and I κ B α degradation

To activate NF- κ B, PMA induces the phosphorylation of IKK, which sequentially phosphorylates I κ B α . The phosphorylated I κ B α dissociates from NF- κ B and is degraded. Therefore, we tested whether eriodictyol affects the PMA-induced phosphorylation of IKK α/β and I κ B α and degradation of I κ B α . As shown in Fig. 3, eriodictyol attenuated PMA-stimulated IKK α/β phosphorylation by controlling the phosphorylation of the serine 176/180 moiety of IKK α/β . PMA treatment increased the phosphorylation of I κ B α , whereas eriodictyol treatment suppressed its phosphorylation. Moreover, PMA treatment increased the degradation of I κ B α , whereas eriodictyol treatment suppressed its degradation.

Effect of eriodictyol on PMA-induced NF- κ B p65 phosphorylation and nuclear translocation

After its activation, NF- κ B translocates from the cytosol to the nucleus, followed by binding to a specific DNA sequence.




Fig. 3. Effect of eriodictyol on PMA-induced IKK phosphorylation, IκBα phosphorylation, and IκBα degradation in NCI-H292 cells. NCI-H292 cells were incubated with varying concentrations of eriodictyol for 24 h and treated with 50 ng/mL PMA for 30 min. Cytoplasmic extracts were fractionated and then subjected to western blot analysis using phospho-specific IκBα (Ser 32/36) or anti-IκBα antibodies. Whole cell lysates were prepared and then subjected to western blot analysis using phospho-specific IKKα/β (Ser 176/180) antibodies. Equal protein loading was evaluated via β-actin levels. *Significantly different from control ($p < 0.05$). †Significantly different from PMA alone ($p < 0.05$). cont, control; E, eriodictyol; IκBα, inhibitory kappa B alpha; IKK, inhibitory kappa B kinase. Concentration unit is μM.

This NF-κB/DNA assembly recruits RNA polymerase, and the resulting mRNA is translated into the specific proteins, including MUC5AC mucins. The transcriptional activity of NF-κB p65 is dependent on its phosphorylation. As shown in Fig. 4, PMA treatment increased the phosphorylation of p65, whereas eriodictyol treatment suppressed its phosphorylation. Eventually, eriodictyol decreased the nuclear translocation of NF-κB p65 stimulated by PMA.

DISCUSSION

As mentioned above, mucolytics, expectorants, and glucocorticoids have been utilized for pharmacotherapy of pulmonary diseases that exhibit hypersecretion of airway mucus; however, these drugs have limited clinical efficacy in regulating such diseases and elicit diverse side effects (Li *et al.*, 2020). Thus, it is essential to develop novel agents that regulate production and/or secretion of mucins by controlling their biosynthesis and/or degradation. Achieving this may require investigating natural compounds (derived from diverse medicinal plants that are used empirically for alleviating inflammatory pulmonary diseases), with respect to the activity to regulate abnormal secretion and/or production of mucins. Our results showed that eriodictyol, a flavonoid with anti-inflammatory activity, decreased MUC5AC gene expression and mucin production stimulated by PMA (Fig. 1, 2). These results suggest that eriodictyol can regulate the gene and protein expression of pulmonary mucin by directly acting on airway epithelial cells. This is the first study to report about the regulatory activ-




Fig. 4. Effect of eriodictyol on PMA-induced NF-κB p65 phosphorylation and translocation in NCI-H292 cells. Nuclear protein extracts were prepared and subjected to western blot analysis using phospho-specific p65 (Ser 536) antibodies and antibodies against p65. p84 was used as a loading control. The results shown are the representative of three independent experiments. *Significantly different from control ($p < 0.05$). †Significantly different from PMA alone ($p < 0.05$). cont, control; E, eriodictyol. Concentration unit is μM.

ity of eriodictyol on airway mucin production.

Eriodictyol was reported to suppress the IL-1β-mediated inflammation of chondrocytes, by attenuating NF-κB activation, and to downregulate the IL-1β-stimulated overproduction of PGE2, nitric oxide, and COX-2 (Wang *et al.*, 2018). In the lipopolysaccharide-mediated acute lung injury mice model, eriodictyol dramatically reduced the expression levels of IL-6, PGE2, IL-1β, and TNF-α in the bronchoalveolar lavage fluid. In addition, the activation of COX-2/NLRP3/NF-κB and Nrf2 signaling was attenuated by eriodictyol (Wang *et al.*, 2020). Notably, a similar report confirmed that eriodictyol could function as an anti-inflammatory agent by protecting against *Staphylococcus aureus*-mediated lung injury (Xuewen *et al.*, 2018). These reports indicate the need to investigate the mechanism of action of eriodictyol involved in mucin gene expression and production, focusing on the NF-κB signaling pathway.

As a multifunctional transcription regulator, NF-κB signaling commonly exists in eukaryotic cells. NF-κB activation occurs by preferentially inducing the phosphorylation of the IKKs, which then activate IκBα phosphorylation. Consequently, the dissociated form of phosphorylated IκBα accumulates and is degraded by the proteasome. NF-κB subunits (p65 and p50) are then released and enter the nucleus, where they bind to DNA (Nie *et al.*, 2012; Liu *et al.*, 2020). The NF-κB signaling pathway plays a crucial role in mediating the biological functions associated with immunity and inflammation (Huang *et al.*, 2018; Lee *et al.*, 2019; Shang *et al.*, 2019). Under pathological airway conditions, NF-κB was found to be involved in mucin hypersecretion and cytokine activity regulation (Liu *et al.*, 2020), and its abnormal activation has been observed in patients with asthma (Huang *et al.*, 2018). Several groups of scientists reported that the gene expression and production of MUC5AC mucin might be induced by the inflammatory mediators that stimulate the activity of transcription factors including NF-κB (Fujisawa *et al.*, 2009; Kurakula *et al.*, 2015; Garvin

et al., 2016). PMA induces airway MUC5AC gene expression and mucin production, and NF- κ B signaling is involved in this activity (Ishinaga et al., 2005; Laos et al., 2006; Wu et al., 2007; Kim et al., 2012).

In our study, eriodictyol suppressed NF- κ B p65 phosphorylation and nuclear translocation by acting on the steps of the phosphorylation and degradation of I κ B α , in human airway epithelial cells (Fig. 3, 4). Therefore, the pharmacological effect of eriodictyol may be partly exerted on MUC5AC gene expression and mucin production by reducing I κ B α degradation and NF- κ B p65 nuclear translocation.

Collectively, these results indicate that the inhibitory activity of eriodictyol on airway mucin gene expression and production might be mediated by controlling PMA-stimulated I κ B α degradation and NF- κ B p65 nuclear translocation. Therefore, eriodictyol could possibly be used as an effective novel mucoregulator for inflammatory pulmonary diseases. It is desirable to modify the chemical structure of eriodictyol to obtain an optimal compound that will show the most effective regulatory effect on the secretion and/or production of pulmonary mucus.

CONFLICT OF INTEREST

The authors have declared that there is no conflict of interest.

ACKNOWLEDGMENTS

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2014R1A6A1029617).

REFERENCES

Adler, K. B. and Li, Y. (2001) Airway epithelium and mucus: intracellular signaling pathways for gene expression and secretion. *Am. J. Respir. Cell Mol. Biol.* **25**, 397-400.

Choi, B. S., Kim, Y. J., Choi, J. S., Lee, H. J. and Lee, C. J. (2019) Obtusifolin isolated from the seeds of *Cassia obtusifolia* regulates the gene expression and production of MUC5AC mucin in airway epithelial cells via affecting NF- κ B pathway. *Phytother. Res.* **33**, 919-928.

Deshpande, R. R., Tiwari, A. P., Nyayanit, N. and Modak, M. (2020) In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2. *Eur. J. Pharmacol.* **886**, 173430.

Eniafe, G. O., Metibemu, D. S. and Omotuyi, O. I., Ogunleye, A. J., Inyang, O. K., Adedokun, N. S., Adeniran, Y. O., Adewumi, B., Enejoh, O. A., Osunmuyiwa, J. O., Shodehinde, S. A. and Oyeneyin, O. E. (2018) *Agemone mexicana* flavanones; apposite inverse agonists of the β 2-adrenergic receptor in asthma treatment. *Bioinformation* **14**, 60-67.

Fujisawa, T., Velichko, S., Thai, P., Hung, L. Y., Huang, F. and Wu, R. (2009) Regulation of airway MUC5AC expression by IL-1 β and IL-17A; the NF- κ B paradigm. *J. Immunol.* **183**, 6236-6243.

Garvin, L. M., Chen, Y., Damsker, J. M. and Rose, M. C. (2016) A novel dissociative steroid VBP15 reduces MUC5AC gene expression in airway epithelial cells but lacks the GRE mediated transcriptional properties of dexamethasone. *Pulm. Pharmacol. Ther.* **38**, 17-26.

Huang, W. C., Wu, L. Y., Hu, S. and Wu, S. J. (2018) Spilanthal inhibits COX-2 and ICAM-1 expression via suppression of NF- κ B and MAPK signaling in interleukin-1 β -stimulated human lung epithelial cells. *Inflammation* **41**, 1934-1944.

Ishinaga, H., Takeuchi, K., Kishioka, C., Suzuki, S., Basbaum, C. and Majima, Y. (2005) Pranlukast inhibits NF- κ B activation and MUC2 gene expression in cultured human epithelial cells. *Pharmacology* **73**, 89-96.

Islam, A., Islam, M. S., Rahman, M. K., Uddin, M. N. and Akanda, M. R. (2020) The pharmacological and biological roles of eriodictyol. *Arch. Pharm. Res.* **43**, 582-592.

Kim, J. O., Sikder, M. A., Lee, H. J., Rahman, M., Kim, J. H., Chang, G. T. and Lee, C. J. (2012) Phorbol ester or epidermal growth factor-induced MUC5AC mucin gene expression and production from airway epithelial cells are inhibited by eriodictyol and wogonin. *Phytother. Res.* **26**, 1784-1788.

Kurakula, K., Hamers, A. A., van Loenen, P. and de Vries, C. J. (2015) 6-Mercaptopurine reduces cytokine and Muc5ac expression involving inhibition of NF- κ B activation in airway epithelial cells. *Respir. Res.* **16**, 73.

Laos, S., Baekstrom, D. and Hansson, G. C. (2006) Inhibition of NF- κ B activation and chemokine expression by the leukocyte glycoprotein, CD43, in colon cancer cells. *Int. J. Oncol.* **28**, 695-704.

Lee, J. W., Ryu, H. W., Lee, S. U., Kim, M. G., Kwon, O. K. and Kim, M. O., Oh, T. K., Lee, J. K., Kim, T. Y., Lee, S. W., Choi, S., Li, W. Y., Ahn, K. S. and Oh, S. R. (2019) *Pistacia weinmannifolia* ameliorates cigarette smoke and lipopolysaccharide-induced pulmonary inflammation by inhibiting interleukin-8 production and NF- κ B activation. *Int. J. Mol. Med.* **44**, 949-959.

Li, J. D., Dohrman, A. F., Gallup, M., Miyata, S., Gum, J. R., Kim, Y. S., Nadel, J. A., Prince, A. and Basbaum, C. B. (1997) Transcriptional activation of mucin by *Pseudomonas aeruginosa* lipopolysaccharide in the pathogenesis of cystic fibrosis lung disease. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 967-972.

Li, X., Jin, F., Lee, H. J. and Lee, C. J. (2020) Recent advances in the development of novel drug candidates for regulating the secretion of pulmonary mucus. *Biomol. Ther. (Seoul)* **28**, 293-301.

Lillehoj, E. R. and Kim, K. C. (2002) Airway mucus: its components and function. *Arch. Pharm. Res.* **25**, 770-780.

Liu, Y., Zhang, B., Zhang, T., Wang, H., Peng, L. and Zhou, L. (2020) Effect of NF- κ B signal pathway on mucus secretion induced by atmospheric PM 2.5 in asthmatic rats. *Ecotoxicol. Environ. Saf.* **190**, 10094.

Nie, Y. C., Wu, H., Li, P. B., Xie, L. M., Luo, Y. L., Shen, J. G. and Su, W. W. (2012) Naringin attenuates EGF-induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs-AP-1 and IKKs-I κ B-NF- κ B signaling pathways. *Eur. J. Pharmacol.* **690**, 207-213.

Rose, M. C. and Voynow, J. A. (2006) Respiratory tract mucin genes and mucin glycoproteins in health and disease. *Physiol. Rev.* **86**, 245-278.

Seo, H. S., Sikder, M. A., Lee, H. J., Ryu, J. and Lee, C. J. (2014) Apigenin inhibits tumor necrosis factor- α -induced production and gene expression of mucin through regulating nuclear factor- κ B signaling pathway in airway epithelial cells. *Biomol. Ther. (Seoul)* **22**, 525-531.

Shang, J., Liu, W., Yin, C., Chu, H. and Zhang, M. (2019) Cucurbitacin E ameliorates lipopolysaccharide-evoked injury, inflammation and MUC5AC expression in bronchial epithelial cells by restraining the HMGB1-TLR4-NF- κ B signaling. *Mol. Immunol.* **114**, 571-577.

Shao, M. X., Ueki, I. F. and Nadel, J. A. (2003) TNF- α converting enzyme mediated MUC5AC mucin expression in cultured human airway epithelial cells. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 11618-11623.

Takeyama, K., Dabbagh, K., Lee, H., Agusti, C., Lausier, J. A., Ueki, I. F., Grattan, K. M. and Nadel, J. A. (1999) Epidermal growth factor system regulates mucin production in airways. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 3081-3086.

Wang, X., Deng, R., Dong, J., Huang, L., Li, J. and Zhang, B. (2020) Eriodictyol ameliorates lipopolysaccharide-induced acute lung injury by suppressing the inflammatory COX-2/NLRP3/NF- κ B pathway in mice. *J. Biochem. Mol. Toxicol.* **34**, e22434.

Wang, Y., Chen, Y., Chen, Y., Zhou, B., Shan, X. and Yang, G. (2018) Eriodictyol inhibits IL-1 β -induced inflammatory response in human osteoarthritis chondrocytes. *Biomed. Pharmacother.* **107**,

1128-1134.

- Wu, D. Y., Wu, R., Reddy, S. P., Lee, Y. C. and Chang, M. M. (2007) Distinctive epidermal growth factor receptor/extracellular regulated kinase-independent and -dependent signaling pathways in the induction of airway mucin 5B and mucin 5AC expression by phorbol 12-myristate 13-acetate. *Am. J. Pathol.* **170**, 20-32.
- Xuewen, H., Ping, O., Zhongwei, Y., Zhongqiong, Y., Hualin, F., Juchun, L., Changliang, H., Gang, S., Zhixiang, Y., Xu, S., Yuanfeng, Z., Lixia, L. and Lizhi, Y. (2018) Eriodictyol protects against Staphylococcus aureus-induced lung cell injury by inhibiting alpha-hemolysin expression. *World J. Microbiol. Biotechnol.* **34**, 64.
- Zhang, Y., Zhang, R. and Ni, H. (2019) Eriodictyol exerts potent anti-cancer activity against A549 human lung cancer cell line by inducing mitochondrial-mediated apoptosis, G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signalling pathway. *Arch. Med. Sci.* **16**, 446-452.